HansBiomed Corporation (KOSDAQ:042520)

Market Cap	278.10B +174.2%
Revenue (ttm)	124.81B +45.9%
Net Income	-19.66B
EPS	-1,432.07
Shares Out	14.26M
PE Ratio	n/a
Forward PE	12.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	126,714
Open	19,600
Previous Close	19,060
Day's Range	19,020 - 20,350
52-Week Range	6,970 - 57,800
Beta	1.99
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2026

About HansBiomed

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product tha...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 299
• Stock Exchange: KOSDAQ
• Ticker Symbol: 042520

Financial Performance

In fiscal year 2025, HansBiomed's revenue was 89.78 billion, an increase of 10.65% compared to the previous year's 81.14 billion. Losses were -31.34 billion, 333.9% more than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 20, 2026

Data Sources Report a data error